title: Targeted therapies: HER2-positive breast cancer-sifting through many good options.
authors: Dana-Farber Cancer Institute, Harvard University School of Medicine, Breast Oncology Center, 450 Brookline Avenue, Boston, MA 02215, USA. ikrop@partners.org
authors: Ian E
authors: IE
authors: Krop
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011799:Quinazolines / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D017239:Paclitaxel; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases
references: J Clin Oncol. 2013 Jun 1;31(16):1947-53
references: 23509322
references: Lancet Oncol. 2012 Feb;13(2):135-44
references: 22257523
references: J Clin Oncol. 2009 Apr 20;27(12):1999-2006
references: 19289619
references: J Clin Oncol. 2013 Mar 20;31(9):1157-63
references: 23382472
references: Clin Cancer Res. 2009 Feb 15;15(4):1452-9
references: 19228746
references: N Engl J Med. 2012 Jan 12;366(2):109-19
references: 22149875
references: N Engl J Med. 2006 Dec 28;355(26):2733-43
references: 17192538
references: Lancet. 2012 Feb 18;379(9816):633-40
references: 22257673
references: N Engl J Med. 2001 Mar 15;344(11):783-92
references: 11248153